LOPINAVIR AND RITONAVIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lopinavir And Ritonavir, and when can generic versions of Lopinavir And Ritonavir launch?
Lopinavir And Ritonavir is a drug marketed by Lannett Co Inc, Hetero Labs Ltd Iii, Laurus, and Mylan Labs Ltd. and is included in four NDAs.
The generic ingredient in LOPINAVIR AND RITONAVIR is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lopinavir And Ritonavir
A generic version of LOPINAVIR AND RITONAVIR was approved as lopinavir; ritonavir by LANNETT CO INC on December 27th, 2016.
Summary for LOPINAVIR AND RITONAVIR
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 340 |
Patent Applications: | 171 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LOPINAVIR AND RITONAVIR at DailyMed |
Recent Clinical Trials for LOPINAVIR AND RITONAVIR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Washington | Phase 1 |
University of Wisconsin, Madison | Phase 1 |
Wisconsin Partnership Program | Phase 1 |
Pharmacology for LOPINAVIR AND RITONAVIR
Anatomical Therapeutic Chemical (ATC) Classes for LOPINAVIR AND RITONAVIR
US Patents and Regulatory Information for LOPINAVIR AND RITONAVIR
EU/EMA Drug Approvals for LOPINAVIR AND RITONAVIR
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Mylan Pharmaceuticals Limited | Lopinavir/Ritonavir Mylan | lopinavir, ritonavir | EMEA/H/C/004025 Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients. |
Authorised | yes | no | no | 2016-01-14 | |
AbbVie Deutschland GmbH Co. KG | Kaletra | lopinavir, ritonavir | EMEA/H/C/000368 Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients. |
Authorised | no | no | no | 2001-03-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |